TrialNeuro-oncology2026

TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

Dorsa Sadat Kiaei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.